Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare (Nasdaq: IXHL) has completed Phase 2 patient enrollment in its global Phase 2/3 RePOSA study of IHL-42X, an oral treatment for Obstructive Sleep Apnea (OSA). The study enrolled over 120 patients across 11 U.S. sites, with topline Phase 2 data expected in first half 2025.
The Phase 2 trial is comparing two dose strengths of IHL-42X to placebo over four weeks. The subsequent Phase 3 expansion will evaluate the selected dose over 52 weeks across 440 patients, comparing it to individual components and placebo.
IHL-42X is designed as a once-daily oral fixed dose combination medicine targeting the underlying causes of OSA. The RePOSA study focuses on patients with mild to severe OSA who are intolerant, non-compliant, or naïve to positive airway pressure therapy. The trial aims to support future regulatory submission through the FDA 505(b)(2) pathway.
Incannex Healthcare (Nasdaq: IXHL) has announced a $12.5 million private placement through the sale of 11,574,090 shares at $1.08 per share to institutional investors. The offering includes Series A Warrants to purchase an additional 11,574,090 shares at $2.16 per share, exercisable following stockholder approval with a 2.5-year expiration.
The funds will primarily support the company's IHL-42X clinical program for Obstructive Sleep Apnea (OSA), specifically funding the completion and topline readout of the U.S. Phase 2 study and its expansion into a global Phase 3 study with sites in the U.K. and U.S. Additional proceeds will be used to repay outstanding convertible debentures, working capital, and general corporate purposes.
The private placement, expected to close around March 10, 2025, is being conducted with R. F. Lafferty & Co. as the sole placement agent. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D to accredited investors only.
Incannex Healthcare (Nasdaq: IXHL) reported its fiscal Q2 2025 financial results and business updates. The company announced positive pharmacokinetics (PK) findings for IHL-42X, their oral treatment for Obstructive Sleep Apnea (OSA), supporting a future 505(b)(2) New Drug Application.
Key financial metrics include: G&A expenses of $3.6M USD (down from $5.3M in 2023), R&D expenses of $1.4M USD (down from $2.6M in 2023), and a net loss of $6.3M USD (increased from $4.3M in 2023). Cash position stands at $2.1M USD as of December 31, 2024.
The company established a new OSA Clinical Advisory Board, appointing Dr. Alison Wimms from ResMed as advisor. The global Phase 2/3 'RePOSA' clinical trial is progressing with strong recruitment, with top-line readout expected in H1 2025.
Incannex Healthcare (Nasdaq: IXHL) has appointed Dr. Alison Wimms to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board, where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role. She holds a Ph.D. in Medicine, Master of Medicine in Sleep Medicine, and Bachelor of Science degrees from the University of Sydney.
The appointment supports Incannex's ongoing global Phase 2/3 'RePOSA' clinical study in OSA and demonstrates the company's commitment to innovation in OSA treatment. Dr. Wimms will provide guidance on IHL-42X late-stage clinical development as part of her advisory role.
Incannex Healthcare (NASDAQ: IXHL) has announced positive topline results from its pharmacokinetics (PK) study of IHL-42X, a novel oral combination medicine combining dronabinol and acetazolamide for treating Obstructive Sleep Apnea (OSA).
The study demonstrated successful bioavailability of IHL-42X, achieving similar PK profiles and equivalent total drug exposure levels compared to reference listed drugs (RLD). The trial involved 125 participants across two Australian sites, with 114 completing all treatment periods. The study evaluated four treatment regimens: IHL-42X in fasted and fed states, and individual components in fasted states.
Key findings showed no substantial food effect on acetazolamide exposure, though THC exposure increased when IHL-42X was administered with food. Safety results were favorable, with no serious adverse events reported. The data supports a potential FDA 505(b)(2) application and will inform the analysis of upcoming Phase 2/3 clinical trials.
Incannex Healthcare (Nasdaq: IXHL) reported its fiscal Q1 2025 financial results and business updates. The company secured strategic financing of up to $59.0 million, including a $50 million equity line of credit and $9.0 million in convertible debentures. Key developments include FDA and MHRA clearance for the Phase 2b PsiGAD2 trial and completion of dosing in the IHL-42X bioavailability trial. Financial results show G&A expenses of $3.4M, R&D expenses of $2.9M, and a net loss of $5.4M. Cash position stood at $3.6M as of September 30, 2024, down from $5.9M in June 2024.
Incannex Healthcare (Nasdaq: IXHL) has appointed Dr. Lou Barbato as Chief Medical Officer, effective immediately. Dr. Barbato brings over 25 years of experience in clinical development, regulatory strategy, and global medical affairs from positions at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He has contributed to multiple successful drug approvals, including Marplan®, Luvox® CR, Marinol®, and Gilenya®. At Incannex, he will lead the development of clinical-stage programs targeting obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.
Incannex Healthcare Inc. (Nasdaq: IXHL) reported fiscal full year 2024 financial results and business updates. Key highlights include:
1. Strategic financing with Arena Investors, providing access to up to $59.0 million USD.
2. Positive top-line results from Phase 2 proof-of-concept clinical trial of PSX-001 for generalized anxiety disorder.
3. Commenced dosing in RePOSA Phase 2/3 clinical trial of IHL-42X for obstructive sleep apnea.
4. Received FDA clearance for PsiGAD2, a Phase 2 clinical trial of PSX-001.
5. Completed redomiciliation to the United States and listed on Nasdaq under ticker IXHL.
Financial results: G&A expenses increased to $17.2 million USD, R&D expenses rose to $12.9 million USD, and net loss was $18.5 million USD for the fiscal year ended June 30, 2024. Cash and cash equivalents were $5.9 million USD as of June 30, 2024.
Incannex Healthcare (Nasdaq: IXHL) has secured a strategic financing deal with Arena Investors for up to $60 million. The agreement includes up to $10 million in secured convertible notes and a $50 million equity line of credit (ELOC). The initial funding tranche of $3.33 million will be received upon closing, with two subsequent tranches available up to $6.67 million. The ELOC allows Incannex to issue and sell up to $50 million of common stock over 36 months.
Incannex plans to use the funds to support ongoing clinical trials of its proprietary drug candidates, including IHL-42X for obstructive sleep apnea, PsiGAD for generalized anxiety disorder, and IHL-675A for rheumatoid arthritis. This financing strengthens Incannex's ability to advance its lead programs through key late-stage clinical milestones.
Incannex Healthcare Inc. (Nasdaq: IXHL) has received FDA approval to conduct a Phase 2 clinical trial for its psilocybin-assisted psychotherapy in patients with Generalised Anxiety Disorder. The trial, named PsiGAD2, will involve approximately 94 patients and follows the successful PsiGAD1 proof-of-concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Scale (HAM-A) score.
The study will evaluate two dose strengths of PSX-001, Incannex's psilocybin formulation, in a double-blind setting. The primary endpoint is the change in HAM-A score two weeks after the second dosing session, with additional endpoints including quality of life measures and safety assessments. The trial is also under review by the UK's MHRA for concurrent implementation in the United Kingdom.